Salarius Pharmaceuticals, Inc. (SLRX)

Salarius Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	-	-	-	1.84	5.23
Revenue Growth (YoY)	-	-	-	-64.84%	51.03%
Cost of Revenue	-	-	-	8.55	6.91
Gross Profit	-	-	-	-6.71	-1.68
Selling, General & Admin	4.96	5.72	7.14	6.1	6.11
Research & Development	0.77	7.17	15.84	-	-
Operating Expenses	5.73	12.89	22.98	6.1	6.11
Operating Income	-5.73	-12.89	-22.98	-12.81	-7.79
Interest & Investment Income	0.16	0.35	0.22	-	-
Other Non Operating Income (Expenses)	-	-	0.01	0.04	0.43
EBT Excluding Unusual Items	-5.58	-12.54	-22.74	-12.77	-7.35
Impairment of Goodwill	-	-	-8.87	-	-
Pretax Income	-5.58	-12.54	-31.61	-12.77	-7.35
Net Income	-5.58	-12.54	-31.61	-12.77	-7.35
Preferred Dividends & Other Adjustments	-	-	-	-	0.4
Net Income to Common	-5.58	-12.54	-31.61	-12.77	-7.75
Shares Outstanding (Basic)	1	0	0	0	0
Shares Outstanding (Diluted)	1	0	0	0	0
Shares Change (YoY)	135.79%	53.66%	28.40%	165.53%	376.61%
EPS (Basic)	-5.79	-30.74	-119.02	-61.73	-99.48
EPS (Diluted)	-5.79	-30.74	-119.02	-61.73	-100.00
Free Cash Flow	-4.53	-12.85	-17.6	-10.2	-10.31
Free Cash Flow Per Share	-4.70	-31.48	-66.26	-49.32	-132.41
Gross Margin	-	-	-	-	-32.11%
Operating Margin	-	-	-	-696.27%	-148.78%
Profit Margin	-	-	-	-693.84%	-148.06%
Free Cash Flow Margin	-	-	-	-554.29%	-197.08%
EBITDA	-5.73	-12.88	-22.97	-12.79	-7.77
EBITDA Margin	-	-	-	-	-148.44%
D&A For EBITDA	0	0.01	0.01	0.02	0.02
EBIT	-5.73	-12.89	-22.98	-12.81	-7.79
EBIT Margin	-	-	-	-	-148.78%

Updated Mar 21, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q